Professional Documents
Culture Documents
Full download Management Of Inpatient Inflammatory Bowel Disease A Comprehensive Handbook Joseph D Feuerstein Adam S Cheifetz Eds ebook online full chapter pdf docx
Full download Management Of Inpatient Inflammatory Bowel Disease A Comprehensive Handbook Joseph D Feuerstein Adam S Cheifetz Eds ebook online full chapter pdf docx
https://ebookmeta.com/product/management-of-inpatient-
inflammatory-bowel-disease-a-comprehensive-handbook-de-joseph-d-
feuerstein-editor/
https://ebookmeta.com/product/inflammatory-bowel-disease-2nd-
edition-wilton-schmidt-cardozo-carlos-walter-sobrado/
https://ebookmeta.com/product/pediatric-inflammatory-bowel-
disease-4th-edition-petar-mamula-judith-r-kelsen-andrew-b-
grossman-robert-n-baldassano-jonathan-e-markowitz/
https://ebookmeta.com/product/small-intestine-disease-a-
comprehensive-guide-to-diagnosis-and-management-hoon-jai-chun/
The Acute Management of Surgical Disease Martin D.
Zielinski (Editor)
https://ebookmeta.com/product/the-acute-management-of-surgical-
disease-martin-d-zielinski-editor/
https://ebookmeta.com/product/the-palgrave-handbook-of-supply-
chain-management-joseph-sarkis/
https://ebookmeta.com/product/nutritional-management-of-renal-
disease-4th-ed-4th-edition-joel-d-kopple/
https://ebookmeta.com/product/medical-management-of-thyroid-
disease-3rd-edition-david-s-cooper/
https://ebookmeta.com/product/caring-for-the-hospitalized-child-
a-handbook-of-inpatient-pediatrics-third-edition-section-on-
hospital-medicine/
Management
of Inpatient
Inflammatory
Bowel Disease
A Comprehensive Handbook
Joseph D. Feuerstein
Adam S. Cheifetz
Editors
123
Management of Inpatient
Inflammatory Bowel Disease
Joseph D. Feuerstein
Adam S. Cheifetz
Editors
Management
of Inpatient
Inflammatory
Bowel Disease
A Comprehensive Handbook
Editors
Joseph D. Feuerstein Adam S. Cheifetz
Harvard Medical School Harvard Medical School
Beth Israel Deaconess Beth Israel Deaconess
Medical Center Medical Center
Boston, MA, USA Boston, MA, USA
© The Editor(s) (if applicable) and The Author(s), under exclusive license to
Springer Science+Business Media, LLC, part of Springer Nature 2022
This work is subject to copyright. All rights are solely and exclusively licensed by
the Publisher, whether the whole or part of the material is concerned, specifically
the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting,
reproduction on microfilms or in any other physical way, and transmission or
information storage and retrieval, electronic adaptation, computer software, or by
similar or dissimilar methodology now known or hereafter developed.
The use of general descriptive names, registered names, trademarks, service
marks, etc. in this publication does not imply, even in the absence of a specific
statement, that such names are exempt from the relevant protective laws and
regulations and therefore free for general use.
The publisher, the authors and the editors are safe to assume that the advice and
information in this book are believed to be true and accurate at the date of
publication. Neither the publisher nor the authors or the editors give a warranty,
expressed or implied, with respect to the material contained herein or for any
errors or omissions that may have been made. The publisher remains neutral with
regard to jurisdictional claims in published maps and institutional affiliations.
v
vi Introduction
vii
viii Contents
Editors
Contributors
ix
x Editors and Contributors
between 2007 and 2013, the 30-day readmission rate was 17.3%,
and the 90-day readmission rate was 29.2%. Patients with CD had
a higher risk of readmission than UC patients (OR 3.90, 95% CI
1.82–8.90) [26]. For IBD readmissions, predictors that have been
reported include opioid use disorder, younger age, mood disorder
(depression and/or anxiety), and lack of follow-up visit after hos-
pitalization [26–29].
Specific risks for hospitalization in IBD have been evaluated
including demographic factors, environmental exposures, and dis-
ease characteristics. The sex, age, race, and socioeconomic status
of patients have variable impact on a patient’s risk of hospitaliza-
tion for IBD. In CD, women have been shown to have a higher
risk of hospitalization than males, especially during the childbear-
ing period [30–33]. For UC, there is conflicting data with some
studies reporting risk of hospitalization being higher in females
and some with a slight male predominance [32, 33]. As with the
onset of IBD, there appears to be a bimodal risk of age for hospi-
talizations in IBD. In the USA, hospitalization rates for UC are
highest in the 20–29-year-old and 70–79-year-old age groups and
for CD are highest in the 20–29-year-old, 50–59-year-old, and
70–79-year-old age groups [30–32]. Within these peaks, younger
patients are higher risk. Elderly patients only account for 25% of
total IBD hospitalizations and overall have less hospitalization
rates when compared with younger adults for both CD and UC
(CD IRR 0.62, 95% CI 0.59–0.65 and UC IRR 0.64, 95% CI
0.57–0.71) [34, 35].
Data on patient’s race and risk of hospitalization is not consis-
tent overall. Earlier studies noted a twofold higher risk of hospi-
talization for whites than blacks (RR 2.18, 95% CI 2.18–2.19) and
higher rates in both white patients and black patients when com-
pared to Hispanics [31, 36]. A more recent evaluation of over
5000 IBD patients did not note any difference in hospitalization
rates between black and white patients [37]. Other studies have
shown that since the 2000s, hospitalization rates have decreased
for non-Hispanic whites but not for black patients and the ratio of
IBD hospitalizations to prevalence of disease was disproportion-
ately higher among non-Hispanic blacks (7.3% compared to 3%
for non-Hispanic whites and 2% for Hispanics) [38, 39]. Lower-
1 Epidemiology and Risk Factors for Hospitalization in Patients… 5
References
1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prev-
alence of the inflammatory bowel diseases with time, based on systematic
review. Gastroenterology. 2012;142(1):46–54.e42. https://doi.
org/10.1053/j.gastro.2011.10.001.
2. Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EVJ. Incidence and
prevalence of Crohn’s disease and ulcerative colitis in Olmsted County,
Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol.
2017;15(6):857–63. https://doi.org/10.1016/j.cgh.2016.10.039.
3. King JA, Underwood FE, Panaccione N, et al. Trends in hospitalisation
rates for inflammatory bowel disease in western versus newly industri-
alised countries: a population-based study of countries in the Organisation
for Economic Co-operation and Development. Lancet. 2019;4(4):287–
95. https://doi.org/10.1016/S2468-1253(19)30013-5.
4. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis:
part II Long-term prognosis. Gut. 1963;4(4):309–15. https://doi.
org/10.1136/gut.4.4.309.
5. Monk M, Mendeloff AI, Siegel CI, Lilienfeld A. An epidemiological
study of ulcerative colitis and regional enteritis among adults in Baltimore.
I. Hospital incidence and prevalence, 1960 to 1963. Gastroenterology.
1968;54(4):198–210. https://doi.org/10.1016/S0016-5085(19)34227-1.
6. Linden G, Moller C. Ulcerative colitis in Finland: one-year incidence in
all hospitals. Dis Colon Rectum. 1971;14(4):264–6. https://doi.
org/10.1016/S0031-3955(05)70404-1.
7. Ritchie JK, Powell-Tuck J, Lennard-Jones J. Clinical outcome of the first
ten years of ulcerative colitis and proctitis. Lancet. 1978;1:1140–3.
8. Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR. Rising hos-
pitalization rates for inflammatory bowel disease in the United States
between 1998 and 2004. Inflamm Bowel Dis. 2007;13:1529–35. https://
doi.org/10.1002/ibd.20250.
9. Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflamma-
tory bowel disease in the United States. Clin Gastroenterol Hepatol.
2007;5:597–601. https://doi.org/10.1016/j.cgh.2007.01.015.
10. Herrinton LJ, Liu L, Fireman B, et al. Time trends in therapies and out-
comes for adult inflammatory bowel disease, northern California, 1998–
2005. Gastroenterology. 2009;137(2):502–11. https://doi.org/10.1053/j.
gastro.2009.04.063.
11. Samuel S, Ingle S, Dhillon S, et al. Cumulative incidence and risk factors
for hospitalization and surgery in a population-based cohort of ulcerative
colitis. Inflamm Bowel Dis. 2013;19(9):1858–66. https://doi.org/10.1097/
MIB.0b013e31828c84c5.CUMULATIVE.
12. Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission
rates of IBD in Canada: a population-based study. Am J Gastroenterol.
2006;101:110–9. https://doi.org/10.1111/j.1572-0241.2006.00330.x.
1 Epidemiology and Risk Factors for Hospitalization in Patients… 7
37. Barnes EL, Kochar B, Long MD. Lack of difference in treatment patterns
and clinical outcomes between black and white patients with inflamma-
tory bowel disease. Inflamm Bowel Dis. 2018;24(12):2634–40. https://
doi.org/10.1093/ibd/izy179.
38. Xu F, Wheaton AG, Liu Y, Lu H, Greenlund KJ. Hospitalizations for
inflammatory bowel disease among medicare fee-for-service beneficia-
ries – United States, 1999–2017. Morb Mortal Wkly Rep.
2019;68(49):1134–8.
39. Nguyen GC, Chong CA, Chong RY. National estimates of the burden of
inflammatory bowel disease among racial and ethnic groups in the United
States. J Crohns Colitis. 2014;8(4):288–95. https://doi.org/10.1016/j.
crohns.2013.09.001.
40. Walker C, Allamneni C, Orr J, et al. Socioeconomic status and race are
both independently associated with increased hospitalization rate among
Crohn’ s disease patients. Sci Rep. 2018;8:1–6. https://doi.org/10.1038/
s41598-018-22429-z.
41. Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J. Effects of
light smoking consumption on the clinical course of Crohn’s disease.
Inflamm Bowel Dis. 2009;15(5):734–41. https://doi.org/10.1002/
ibd.20828.
42. de Boer Visser N, Bryant HE, Hershfield NB. Predictors of hospitaliza-
tion early in the course of Crohn’s disease. A pilot study. Gastroenterology.
1990;99(2):380–5. https://doi.org/10.1016/0016-5085(90)91019-3.
43. Stein AC, Gaetano JN, Jacobs J, Kunnavakkam R, Bissonnette M, Pekow
J. Northern latitude but not season is associated with increased rates of
hospitalizations related to inflammatory bowel disease: results of a multi-
year analysis of a National cohort. PLoS One. 2016;11(8):1–12. https://
doi.org/10.1371/journal.pone.0161523.
44. Don BAC, Goldacre MJ. Absence of seasonality in emergency hospital
admissions for inflammatory bowel disease. Lancet. 1984;2:1156–7.
45. Limketkai BN, Bayless TM, Brant SR, Hut SM. Lower regional and tem-
poral ultraviolet exposure is associated with increased rates and severity
of inflammatory bowel disease hospitalisation. Aliment Pharmacol Ther.
2014;40:508–17. https://doi.org/10.1111/apt.12845.
46. Veloso FT, Ferreira JT, Barros L, Almeida S. Clinical outcome of Crohn’s
disease: analysis according to the Vienna classification and clinical activ-
ity. Inflamm Bowel Dis. 2001;7(4):306–13.
47. Chow D, Sung J, Wu J, Tsoi K, Leong R, Chan FKL. Upper gastrointes-
tinal tract phenotype of Crohn’s disease is associated with early surgery
and further hospitalization. Inflamm Bowel Dis. 2009;15(4):551–7.
https://doi.org/10.1002/ibd.20804.
Routine Management
of Hospitalized Patients 2
with Ulcerative Colitis
Background
Epidemiology
General Principles
Diagnostic Work-Up
Initial Treatment
Monitoring Response
ASUC
Solumedrol 60 mg
IVdaily for 3-5 days
Response No Response
Infliximab or
Transition tooutpatient
cyclosporine/
maintenance therapy
tacrolimus
No Response
Response
Transition tooutpatient
Surgery
maintenance therapy
Dans le cours d’un voyage que nous avons fait à Breslau en 1868,
nous avons pu étudier à loisir le célèbre manuscrit des Chroniques
de Froissart conservé dans la bibliothèque de cette ville. Quoique ce
manuscrit (coté A 29 dans notre classement des mss. du premier
livre) appartienne à une famille représentée par 7 exemplaires dont
4 sont à Paris[363], cependant il offre à partir de 1340, et surtout de
1342, certains développements qui manquent dans les autres
manuscrits de la même famille. Le Froissart de Breslau, dont la
valeur réside principalement dans les belles miniatures de l’école de
Louvain qui illustrent les deux derniers volumes[364], a été exécuté ou
grossé par David Aubert pour Antoine, bâtard de Bourgogne, en[365]
1468 et 1469; par conséquent, jusqu’à ce qu’on ait retrouvé les
développements dont nous parlons dans un manuscrit plus ancien, il
y a lieu de les considérer plutôt comme l’œuvre de David Aubert et
des scribes aux gages de la maison de Bourgogne que comme celle
de Froissart. Cependant, à notre retour en France, nous nous
proposions de solliciter le prêt du ms. de Breslau auprès de la
municipalité de cette ville par l’entremise du gouvernement prussien;
malheureusement, les cruels événements de 1870 et de 1871 ne
nous ont pas permis de donner suite à ce projet. Ayant appris, d’un
autre côté, à la fin de 1868, que les variantes du ms. de Breslau
avaient été copiées au seizième siècle en marge d’un exemplaire de
l’édition de Sauvage qui fait partie de la collection plantinienne
d’Anvers, nous avions prié M. Moretus, propriétaire de cette
collection et héritier des Plantin, de vouloir bien nous autoriser à
prendre communication sur place de cet exemplaire; malgré
l’obligeante entremise de M. le baron de Witte, cette autorisation
nous a été refusée. Plus heureux que nous, M. le baron Kervyn de
Lettenhove a pu donner les variantes du ms. de Breslau, sinon
d’après l’original lui-même, au moins d’après la copie du seizième
siècle inscrite en marge du Froissart de la collection Plantin. Force
nous est donc de reproduire aujourd’hui ces variantes d’après
l’édition du savant éditeur belge (voy. t. IV, p. 479 à 508, et t. V, p.
545 à 548). Seulement, nous avons pensé qu’il importait de ne pas
confondre avec les résultats de notre propre travail des textes qui ne
nous arrivent ainsi que de troisième main; voilà pourquoi nous avons
pris le parti de les publier à part et en supplément à la fin du présent
volume de notre édition.